Advanced development and validation of aliquot-level visual indicators of biospecimen exposure to thawed conditions
Active Project Grant Awarded
- Award ID
- R33CA309724
- Recipient
-
Arizona State University UEI NTLHJXM55KZ6 Part of Arizona Board Of Regents
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $353,601
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date 16% complete
- Place of performance
- Tempe, AZ 85287, USA
Award details come from USAspending.gov.
About this award
The National Cancer Institute awarded Arizona State University $353,601 on May 8, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate aliquot-level visual indicators of biospecimen exposure to thawed conditions.
The project, titled "Advanced Development and Validation of Aliquot-Level Visual Indicators of Biospecimen Exposure to Thawed Conditions," builds on prior R21 exploratory work and focuses on developing kinetically unique, autocatalytic, color-changing permanganate/oxalate reactions in melting point-depressed aqueous solvents as simple, inexpensive visual trackers. These trackers are designed to monitor biospecimen exposure to inappropriately warm conditions, including temperature thresholds as low as −18°C, −37°C, and −67°C. The work addresses the critical pre-analytical problem of biospecimen degradation during thawed storage; improper sample handling and storage currently generate unacceptably large numbers of costly false leads in biomedical research. The project aims to provide easy-to-use, individual aliquot-level thawed-state indicators that researchers can employ for quality assurance and control.
Work is performed in Tempe, Arizona. The award period runs from May 8, 2026, through April 30, 2029. This is a Project Grant, the standard assistance type for investigator-initiated research.
Description
- Abstract
- Many biological analytes of interest to both clinical oncologists and cancer researchers are unstable when the unfixed biospecimens in which they reside are exposed to thawed conditions. For example, american society of clinical oncology / college of american pathologists guidelines state that the post-excision-up-to-fixation exposure time span for tissues collected for clinical HER2 testing in breast cancer must be less than 1 hour. For blood plasma/serum and many types of tissue specimens that are to be frozen, the proper cold storage temperature is well below the common laboratory freezer temperature of -20 °c. For this and many other reasons, every year improprieties and inconsistencies in pre-analytical sample handling and storage generate unacceptably large numbers of costly false leads in biomedical research. Unsurprisingly, experts in the field agree that this problem must be minimized immediately. Currently there are few tools and not so much as one widely accepted approach by which to implement evidence-based tracking of biospecimen exposure to thawed conditions. In practice, IT is actually quite rare for biomedical researchers to employ any evidence-based QA/QC tools at all-which suggests that easy-to-use, individual aliquot-level thawed-state indicators could have a major impact on improving biospecimen quality tracking and therefore actual biospecimen quality. In 2022, the PI's lab was awarded an R21 grant through the NCI's imat program to pursue development of the kinetically unique, autocatalytic, color-changing permanganate/oxalate reaction in melting point-depressed aqueous solvents as simple (i.e., user friendly), inexpensive, visual trackers of biospecimen exposure to inappropriately warm conditions, including temperature thresholds as low as -18 °c, -37 °c and -67 °c. The chemistry for 14 targeted time-temperature indicators (ttis) has been successfully developed. Under this proposed project, the PI's lab seeks to maximize the color intensity of the ttis (advanced development) and to develop and validate user-friendly, self-contained, customer-activatable physical devices that will ultimately translate the unique chemistry that underpins the ttis into market-ready products that provide aliquot-level color-changing indicators of biospecimen exposure to thawed or inappropriately warm conditions that make IT essentially impossible for anyone handling the specimens to ignore their integrity status. This will be accomplished under two specific aims: specific aim 1: leverage our recently developed, AI-enabled chemical kinetics simulations to develop and validate permanganate/oxalate reaction-based ttis with maxed-out, 5X color intensity that run for as little as 5 minutes to as long as 2.5 HRS at 25 °c-and that have melting points of 0 °c, -18 °c, -37 °c, or -67 °c. Specific aim 2: develop and performance-test several physical device designs that will provide self-contained, aliquot-level, user-activatable, color-changing TTI devices that anyone can use to track the exposure of biospecimens to thawed / inappropriately warm conditions.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Wainamics, Inc. | $119,804 |
Quick answers
Who received award R33CA309724?
R33CA309724 was awarded to Arizona State University by National Cancer Institute (National Institutes of Health) on May 8, 2026.
How much is award R33CA309724 worth?
$353,601 has been obligated on R33CA309724.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award